Nasdaq:BNTX

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates…

7 hours ago